[REVISION HISTORY]

DRC Ebola outbreak expands and impacts healthcare workers

Updated 59 times since CLSTR started tracking revisions of this situation.

What changed

2026-10-13 14:57 UTC → 2026-10-14 18:32 UTC · added ~~removed~~

The Bundibugyo-strain Ebola outbreak in the Democratic Republic of Congo (DRC) continues to escalate, marking the deadliest epidemic in the country’s history. As of mid-October 2026, confirmed cases have ~~exceeded 9,000~~ surpassed 9,000, with ~~deaths surpassing 4,300.~~ the Health Ministry reporting 4,381 deaths. The case fatality rate is approximately 48.3%, though officials warn that confirmed figures may only represent one-third of actual infections due to undetected cases. The virus has spread across 65 ~~regions~~ health zones in seven provinces, ~~surpassing the scale of the 2018–2020 epidemic. The epidemic is intensifying in eastern provinces, particularly~~ primarily in ~~North Kivu, which accounts for nearly 40% of new confirmed cases. In~~ the ~~Mambasa territory, a lack of mobile laboratories~~ north and ~~a shortage of beds in dedicated centers continue to hamper response efforts. While health authorities report a contact tracing rate~~ east. Containment efforts face significant hurdles, including ongoing armed conflict, community mistrust of ~~approximately 81%~~ medical personnel, and ~~some recent recoveries, including a doctor~~ limited healthcare infrastructure. Many deaths are occurring within communities rather than in ~~Tshopo province, the rapid transmission rate remains a critical concern.~~ treatment centers. To ~~combat~~ address the lack of approved treatments for this specific strain, ~~clinical trials are underway. One study is evaluating obeldesivir, an antiviral pill developed by Gilead, as a post-exposure prophylaxis. Additionally,~~ the ~~BRAVO study, coordinated by Médecins Sans Frontières (MSF),~~ World Health Organization (WHO) is ~~testing~~ launching the ~~effectiveness~~ ‘Tumaini’ clinical trial platform. This initiative, expected to begin before the end of October, will test vaccines against the Bundibugyo virus. The first phase will utilize the Ervebo ~~vaccine. This trial~~ vaccine, which is already approved for the Zaire strain, while the project aims to ~~include up to 20,000 participants, focusing on pregnant women and frontline workers in~~ eventually integrate candidate vaccines from the ~~Ituri~~ University of Oxford and ~~North Kivu provinces. The human toll remains severe, with children representing over one~~ Moderna. Regional spread is also a growing concern; health authorities in ~~four~~ Kenya have confirmed ~~cases and approximately one in three deaths. Containment efforts continue to face logistical, security, and social hurdles,~~ two imported cases, including ~~physical insecurity and mistrust~~ a 39-year-old man who is a close relative of ~~authorities.~~ the first patient. Kenyan officials have placed 108 contacts in quarantine and tightened border screenings.

Versions

Only revisions since CLSTR began indexing content versions appear here. Showing the 50 most recent. Select a version to see what changed compared to the one before it.